Senti Biosciences (SNTI) Change in Receivables (2021 - 2025)
Senti Biosciences' quarterly Change in Receivables came in at -$325000.0 in Q4 2025, down 282.35% year-on-year from $178225.8 in Q4 2024, and up 83.13% quarter-over-quarter from -$1.9 million in Q3 2025.
Senti Biosciences has reported Change in Receivables for 5 years, with the latest figure at -$325000.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Receivables fell 282.35% year-over-year to -$325000.0; the trailing twelve-month figure through Dec 2025 stood at -$374000.0 (down 895.74% YoY), and the FY2025 full-year result was -$374000.0, down 895.74% from the prior year.
- Change in Receivables for Q4 2025 stood at -$325000.0, up from -$1.9 million in the prior quarter.
- The five-year high for Change in Receivables was $1.9 million in Q4 2023, with the low at -$1.9 million in Q3 2025.
- Average Change in Receivables over 5 years is $75882.4, with a median of -$38000.0 recorded in 2024.
- Peak annual rise in Change in Receivables reached 3774.36% in 2025, while the deepest fall reached 1022.01% in 2025.
- Tracing SNTI's Change in Receivables over 5 years: stood at $50000.0 in 2021, then surged by 162.0% to $131000.0 in 2022, then soared by 1384.73% to $1.9 million in 2023, then tumbled by 104.37% to -$85000.0 in 2024, then sank by 282.35% to -$325000.0 in 2025.
- The last three Change in Receivables figures came in at -$325000.0 (Q4 2025), -$1.9 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -325,000.00 |
| Dec 31, 2025 | -325,000.00 |
| Sep 30, 2025 | -1.93 Mn |
| Sep 30, 2025 | -1.93 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 445,000.00 |
| Mar 31, 2025 | 445,000.00 |
| Dec 31, 2024 | -85,000.00 |
| Dec 31, 2024 | -85,000.00 |
| Sep 30, 2024 | 209,000.00 |
| Sep 30, 2024 | 209,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Mar 31, 2024 | -38,000.00 |
| Mar 31, 2024 | -38,000.00 |
| Dec 31, 2023 | 1.95 Mn |
| Dec 31, 2023 | 1.95 Mn |
| Sep 30, 2023 | -509,000.00 |
| Sep 30, 2023 | -509,000.00 |
| Jun 30, 2023 | -135,000.00 |
| Jun 30, 2023 | -135,000.00 |
| Mar 31, 2023 | 135,000.00 |
| Mar 31, 2023 | 135,000.00 |
| Dec 31, 2022 | 131,000.00 |
| Dec 31, 2022 | 131,000.00 |
| Sep 30, 2022 | -90,000.00 |
| Sep 30, 2022 | -90,000.00 |
| Jun 30, 2022 | 143,000.00 |
| Jun 30, 2022 | 143,000.00 |
| Mar 31, 2022 | -53,000.00 |
| Mar 31, 2022 | -53,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Dec 31, 2021 | 50,000.00 |